Vasoconstrictor Agents
PreclinicalSmall molecule
Vasoconstrictor Agents is one of 36 small molecule programs targeting Sepsis. It is currently in Preclinical.
2
Indications
2
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
112 competitors in Sepsis
#DrugCompanyPhaseTrials
1Olumiant
Eli LillyPhase 2
N-Acetylcysteine (NAC) Treatment
TThe First Affiliated Hospital of Soochow University
Phase 3
Kineret
SSwedish Orphan Biovitrum
Phase 2
Decadron
AAspen Global Incorporated
Phase 2
Heparin Sodium
BBaxter Healthcare Corporation
Phase 2
Actemra
CCelltrion
Phase 2
Nafamostat Mesylate
EEnsysce Biosciences
Phase 3
Hydrocortisone Administration
UUniversity of Virginia
Phase 3
AZD4144
AstraZenecaPhase 2
Simdax
Orion Corporation, Orion PharmaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sepsis1 trial
Observational Study About the Use of Perfusion Index to Use Vasopressor in Sepsis
Recruiting·—··NCT06860438·40 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Vasoconstrictor Agents. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details